The effects of rosiglitazone on the neonatal rat cardiomyocyte transcriptome: a temporal analysis

Author:

da Silveira Willian Abraham12,Vazquez-Hidalgo Esteban34,Bartolotta Elesha3,Renaud Ludivine15,Paolini Paul34,Hardiman Gary125

Affiliation:

1. Center for Genomic Medicine, Bioinformatics, Medical University of South Carolina, Charleston, SC, USA

2. Faculty of Medicine, Health & Life Sciences, School of Biological Sciences, Institute for Global Food Security (IGFS), Belfast, Northern Ireland, UK

3. Department of Biology, San Diego State University, San Diego, CA, USA

4. Computational Science Research Center, San Diego State University, San Diego, CA, USA

5. Department of Medicine, Medical University of South Carolina, Charleston, SC, USA

Abstract

Aim: The objective was to determine via high-throughput RNA sequencing the temporal effects of rosiglitazone (Avandia®) on the neonatal rat ventricular myocyte transcriptome. Materials & methods: Neonatal rat ventricular myocytes (NRVMs) were exposed to rosiglitazone in vitro. Meta analyses utilized temporal comparisons of 0.5 h control versus 0.5 h treatment, 0.5 h treatment versus 24 h treatment and 24 h treatment versus 48 h treatment. Results: Time dependent responses were observed. At 0.5 h, the PI3K-AKT signaling pathway was impacted. At 24 h endoplasmic reticulum activity and protein degradation were altered. At 48 h, oxytocin signaling was perturbed. Conclusion: The effects of rosiglitazone occured early and increased in magnitude over time. A protective molecular response was triggered at 24 h and maintained until 48 h. In parallel, a response that can cause cardiac damage was activated. Our findings suggest that rosiglitazone has deleterious effects.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Genetics,Molecular Medicine

Reference59 articles.

1. Thiazolidinediones

2. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus

3. PPARγ signaling and metabolism: the good, the bad and the future

4. (FDA) USFaDA. Highlights of prescribing information: AVANDIA® (rosiglitazone maleate) tablets (2008). www.accessdata.fda.gov/drugsatfda_docs/label/2008/021071s034lbl.pdf

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3